Peptides
Chonluten
Also called Chonluten
Chonluten is marketed for easier breathing and respiratory support, including to people concerned about smoking history or slow recovery after illness. These are understandable goals, but the cited laboratory work does not show that it repairs lungs or treats asthma or COPD. It is not a rescue treatment for breathlessness.
Dosage & duration
One seller’s oral capsule directions
Gavau Chonluten listing
Reported use · unapproved regimen- Dose
- 1–2 capsules per administration
- How often
- Twice daily with meals
- How long
- 1 month in the seller instructions
The seller suggests repeating after 3–6 months; neither the course nor repeat interval establishes a clinical respiratory benefit. Capsule directions are not a dose of pure injectable EDG.
Sources: 2
Do not convert capsule fill weight to an injection amount or stop an inhaler based on a supplement protocol.
Why people consider Chonluten
Easier breathing in everyday life
-
More comfortable activity
People hope walking or climbing stairs will feel easier.
-
Respiratory recovery
Interest also comes from concerns after illness or a history of smoking.
Why do people research it?
Respiratory resilience and easier activity are the main attractions. Marketing often names chronic lung conditions, but a condition appearing on a product page does not mean a treatment effect was demonstrated.
What does the research show?
The cited experiment exposed a human-derived immune-cell line to peptides and measured inflammatory signals. It did not measure breathing, oxygenation or lung repair in patients. Calling the cells “human” does not change that distinction.
Chonluten with Bronchogen
They are different peptides often sold for overlapping goals. A combined product needs its own ingredient amounts and evidence; two lung-support labels do not establish better treatment together.
What is the useful next step?
Persistent cough, wheeze or reduced exercise tolerance needs an explanation. Keep prescribed respiratory care in place and discuss any supplement. Sudden or severe breathing difficulty requires urgent help, not a peptide dose adjustment.
Model details: Chonluten · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 4.08 h remains an assumed timescale; inflammatory marker changes do not supply elimination.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 4.08 hours
- Absorption half-life assumed
- 1.02 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Oral capsule directions do not establish peptide bioavailability.
- Do not borrow kinetics from unrelated bronchial peptide mixtures.
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
Legacy 4.08 h remains an assumed timescale; inflammatory marker changes do not supply elimination.
chonluten-relative-timing-2026-10 · version 1
Common questions
Can Chonluten repair smoking-related lung damage?
The cited research does not establish that result. A respiratory-support product claim should not substitute for assessment and established care.
Is Chonluten the same as Bronchogen?
No. They are different peptides, even when marketed together for lung-related goals.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- No proven lung-repair result follows from a support claim.
- Compared with Bronchogen
- Similar marketing categories do not make them interchangeable.
- Acute symptoms
- New or worsening breathlessness needs appropriate assessment.
- 1. Avolio et al.: peptide effects in THP-1 cells
Original abstract inspected after PMC browser block: cell-line inflammatory signaling, not a respiratory patient trial.
- 2. Gavau Chonluten capsule listing
Seller’s own capsule directions: 1–2 capsules twice daily with meals for 1 month, with a suggested repeat after 3–6 months. Reported product use, not proven treatment or safety.
- 3. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
Legacy 4.08 h remains an assumed timescale; inflammatory marker changes do not supply elimination.
- 4. Khavinson peptides in THP-1 cells, 2022
Original human leukemia-derived monocyte/macrophage cell-line study; EDG identity and inflammatory signaling measurements. No respiratory treatment trial.
Keep reading
Related compounds and examples
Related compounds
Epithalon (Epitalon)
Epithalon for sleep and longevity: reported dose ranges, Epithalamin confusion and why telomere changes do not prove longer life.
Livagen
Livagen is a short peptide studied in liver tissue and isolated blood cells. The research describes changes in cell growth and DNA packaging, not a proven liver-detox or liver-repair treatment in people.
Ovagen
Ovagen for liver and digestive-health questions: capsule directions, comparison with Livagen and limits of detox and liver-repair claims.